My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Omeros Corporation - Common Stock (NQ:OMER)

12.04 +0.03 (+0.25%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

90 Biggest Movers From Yesterday ↗

May 13, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 18, 2022

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...

Via Benzinga

58 Stocks Moving In Thursday's Mid-Day Session ↗

May 12, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 102.6% to $0.1580 after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.

Via Benzinga

Omeros: Q1 Earnings Insights ↗

May 10, 2022

Omeros (NASDAQ:OMER) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros beat estimated earnings by 25.35%,...

Via Benzinga

Omeros Earnings Preview ↗

May 09, 2022

Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Omeros will report an...

Via Benzinga

52 Stocks Moving In Wednesday's Mid-Day Session ↗

May 11, 2022

Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 30, 2022

Gainers Adagio Therapeutics (NASDAQ:ADGI) shares increased by 52.2% to $5.86 during Wednesday's pre-market session. The company's market cap stands at $651.9 million.

Via Benzinga

Earnings Scheduled For May 10, 2022 ↗

May 10, 2022

Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

April 21, 2022

On Thursday, 236 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

April 19, 2022

On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was...

Via Benzinga

Omeros's Return On Capital Employed Insights ↗

March 07, 2022

According to Benzinga Pro, during Q4, Omeros (NASDAQ:OMER) earned $280.62 million, a 1336.05% increase from the preceding quarter. Omeros also posted a total of $30.84 million in...

Via Benzinga

Omeros: Q4 Earnings Insights ↗

March 01, 2022

Omeros (NASDAQ:OMER) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros missed...

Via Benzinga

The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug ↗

January 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In...

Via Benzinga

Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA ↗

January 20, 2022

Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

December 09, 2021

Gainers Applied DNA Sciences (NASDAQ:APDN...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 03, 2021

Gainers Lixte Biotech Holdings (NASDAQ:LIXT

Via Benzinga

Omeros Offloads Cataract Med Omidria To Rayner Surgical In Deal Valued Over $1B ↗

December 02, 2021

Omeros Corporation (NASDAQ: OMER) has agreed to sell Omidria to Rayner Surgical Group Limited for an upfront payment of $125 million with an additional $200...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 02, 2021

Gainers Omeros (NASDAQ:OMER) stock increased by 15.68% to $7.89 during Thursday's pre-market session. The market value of their outstanding shares is at $493.4 million...

Via Benzinga

Omeros: Q3 Earnings Insights ↗

November 09, 2021

Omeros (NASDAQ:OMER) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros...

Via Benzinga

Earnings Outlook For Omeros ↗

November 08, 2021

Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

76 Biggest Movers From Yesterday ↗

November 11, 2021

Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares...

Via Benzinga

Topics Initial Public Offering

Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years ↗

November 05, 2021

Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA...

Via Benzinga

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗

November 02, 2021

The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...

Via Benzinga

3 Beaten-Down Biotech Stocks -- Can They Recover? ↗

October 31, 2021

Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year.

Via The Motley Fool

10 Biggest Price Target Changes For Tuesday ↗

October 19, 2021

Goldman Sachs boosted Walmart Inc. (NYSE:WMT) price...

Via Benzinga

46 Biggest Movers From Yesterday ↗

October 19, 2021

Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial...

Via Benzinga

Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA ↗

October 18, 2021

The FDA issued a Complete Response Letter (CRL) related to Omeros Corporation's (NASDAQ: OMER) marketing application for narsoplimab for hematopoietic...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.